{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T18:47:22Z","timestamp":1773946042202,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1053\/j.ajkd.2015.04.044","type":"journal-article","created":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T19:21:58Z","timestamp":1434396118000},"page":"583-590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC)"],"prefix":"10.1053","volume":"66","author":[{"given":"Ronald D.","family":"Perrone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Neville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlene B.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berenice Y.","family":"Gitomer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana C.","family":"Miskulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank S.","family":"Czerwiec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eslie","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bron","family":"Kisler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Kopko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly B.","family":"Krasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"LeRoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Castedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Schrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Broadbent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2015.04.044_bib1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0272-6386(83)80044-4","article-title":"Epidemiology of adult polycystic kidney disease, Olmsted county, Minnesota: 1935-1980","volume":"2","author":"Iglesias","year":"1983","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2015.04.044_bib2","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2015.04.044_bib3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.ajkd.2015.04.044_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2015.04.044_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/j.ajkd.2009.04.029","article-title":"Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"54","author":"Levey","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2015.04.044_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.yjmcc.2013.01.015","article-title":"Polycystin-2 mutations lead to impaired calcium cycling in the heart and predispose to dilated cardiomyopathy","volume":"58","author":"Paavolaa","year":"2013","journal-title":"Mol Cell Cardiol"},{"issue":"1","key":"10.1053\/j.ajkd.2015.04.044_bib7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for linical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2015.04.044_bib8","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/ki.1992.195","article-title":"Factors affecting the progression of renal disease in autosomal dominant polycystic kidney disease","volume":"41","author":"Gabow","year":"1991","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2015.04.044_bib9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2215\/CJN.02410508","article-title":"Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis","volume":"4","author":"Rizk","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2015.04.044_bib10","unstructured":"Clinical Data Interchange Standards Consortium. 2014 Business case for use of CDISC Standards. http:\/\/cdisc.org\/2014-business-case-use-cdisc-standards. Accessed April 23,\u00a02015."},{"key":"10.1053\/j.ajkd.2015.04.044_bib11","unstructured":"US Food and Drug Administration. Providing regulatory submissions in electronic format\u2014standardized study data. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm292334.pdf. Accessed April 23,\u00a02015."},{"key":"10.1053\/j.ajkd.2015.04.044_bib12","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2015.04.044_bib13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2215\/CJN.04310709","article-title":"The HALT Polycystic Kidney Disease trials: design and implementation","volume":"5","author":"Chapman","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2015.04.044_bib14","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/j.ajkd.2014.08.017","article-title":"GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials","volume":"64","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2015.04.044_bib15","first-page":"2518","article-title":"Decline in estimated\u00a0glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1053\/j.ajkd.2015.04.044_bib16","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1053\/j.ajkd.2014.08.018","article-title":"GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials","volume":"64","author":"Lambers Heerspink","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2015.04.044_bib17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2015.04.044_bib18","first-page":"A90","article-title":"Baseline total kidney volume is associated with end-stage renal disease in patients independently of eGFR in patients with autosomal dominant polycystic disease [abstract]","volume":"63","author":"Marier","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2015.04.044_bib19","doi-asserted-by":"crossref","first-page":"A119","DOI":"10.1053\/j.ajkd.2014.01.444","article-title":"Qualification of total kidney volume as a prognostic biomarker for use in clinical trials evaluating patients with autosomal dominant polycystic disease [abstract]","volume":"63","author":"Perrone","year":"2014","journal-title":"Am J Kidney Disease"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638615007581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638615007581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:40:24Z","timestamp":1759459224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638615007581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0272638615007581"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.04.044","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC)","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2015.04.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}